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Abstract
Introduction: Accelerated atherosclerosis is one of the major causes of morbidity in patients with systemic lupus
erythematosus (SLE). Endothelial dysfunction (ED) is considered an early marker of atherosclerosis. It is a reversible
alteration, thus representing an attractive target for prevention strategies against cardiovascular disease. Studies
have shown that ED occurs in patients with SLE even in the absence of severe, active disease. Hydroxychloroquine
(HCQ) is widely used in SLE to control disease activity, but its use is also associated with an improvement in
long-term prognosis. Beyond the beneficial effect in well-established disease, our hypothesis is that treatment
with HCQ might have a beneficial impact on ED prevention in SLE. The aim of this study was to assess the impact
of early treatment with HCQ on ED in a murine model of SLE.
Methods: Twelve-week-old NZB/W F1 (NZ) and C57BL/6 J mice (controls) were allocated to receive HCQ or vehicle for
6, 12, or 18 weeks. Proteinuria and anti–double-stranded DNA autoantibodies were determined. ED was assessed in
mesenteric arteries (pressurized myography). Nitric oxide (NO) availability and reactive oxygen species (ROS) production
were evaluated. Vascular ROS production was measured with dihydroethidium (DHE) fluorescent dye.
Results: Starting from 18 weeks of age, NZ mice showed a progressive reduction in NO availability, which was
normalized by ascorbic acid and apocynin in the up to 24-week-old group, and partly ameliorated in older animals.
HCQ administration normalized the NO availability in the up to 24-week-old group, with a partial amelioration in the
30-week-old group. DHE analysis revealed a progressive increment of vascular ROS generation among NZ groups,
which was prevented by apocynin. Similarly, in the NZ HCQ-treated group, vascular ROS production was abrogated.
Conclusions: The ED that characterizes this mouse model of SLE is caused by the nicotinamide adenine dinucleotide
phosphate oxidase–driven ROS excess. Very early treatment with HCQ is able to exert vascular protection via an
antioxidant effect.
Introduction
In recent years, the survival of patients with systemic lupus
erythematosus (SLE) has increased substantially. Reasons
for the improved prognosis include earlier diagnosis, en-
hanced recognition of milder forms, and mindful use of
treatments such as glucocorticoids and immunosuppres-
sive agents. However, because of prolonged life expect-
ancy, patients with SLE are now exposed to an increased
risk of morbidity related to the sequelae of disease activity,
side effects of medications, and comorbid conditions, such
as premature cardiovascular (CV) morbidity [1, 2].
Accelerated atherosclerosis is one of the major causes
of CV morbidity and mortality in patients with SLE. Of
note, over the past 3 decades, mortality has been signifi-
cantly reduced for all causes among patients with SLE,
with the exception of CV disease. For these reasons, the
prevention of long-term CV complications in patients
with SLE, while still an unsolved issue, represents a par-
ticularly attractive target for intervention. Beyond the
concomitance with traditional CV risk factors, including
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obesity, hypertension, dyslipidemia, and diabetes melli-
tus, SLE is considered per se responsible for direct detri-
mental effects on the vasculature, which makes SLE
itself a potent, independent CV risk factor [3, 4].
Endothelial dysfunction (ED) is characterized by im-
paired nitric oxide (NO) availability and a concomitant
increased reactive oxygen species (ROS) generation [5].
Such a systemic condition is shared by the majority of CV
risk factors, is recognized as an early and major promoter
for atherosclerosis and thrombosis, and is independently
related to CV events [5]. Interestingly, SLE and athero-
sclerosis share mechanisms such as vascular inflammation,
ROS excess, immune complexes, and complement activa-
tion, which are all able to elicit ED. Of note, ED is a revers-
ible alteration, thus representing a potentially attractive
target for preventive intervention against CV disease.
Hydroxychloroquine (HCQ) is an antimalarial com-
pound with immunomodulatory properties widely used in
SLE owing to its multiple beneficial effects, including con-
trol of disease activity, reduction of damage accrual, im-
provement of survival, and a relatively safe profile [6–10].
In recent years, HCQ therapy has been associated with
an improvement of CV prognosis in SLE. A positive
effect on traditional CV risk factors and on thrombotic
risk has been described in SLE [11–14]; moreover, a
beneficial effect on vascular reactivity indices has also
been reported [15, 16].
However, it is still unclear whether the protective CV ef-
fect of antimalarials is the indirect result of better control
of disease activity or, alternatively, a direct effect of HCQ
on the endothelial microenvironment. The availability of
lupus murine models offers a great opportunity to study
this relationship in a “simplified” setting to improve under-
standing of the role of the multiple contributing factors.
Recently, Gómez-Guzmán et al. [17] have shown that
short-term treatment with HCQ started at a late disease
stage is able to reverse ED at the level of large arteries in a
murine model of SLE, an effect mediated by a reduction
of the nicotinamide adenine dinucleotide phosphate
[NAD(P)H] oxidase activity, which is a major ROS source.
Beyond the beneficial effect of the antimalarial in condi-
tions of well-established disease, early HCQ use has been
also associated with delayed SLE onset in humans [18].
We hypothesized that treatment with HCQ before the
onset of the full-blown disease might delay or even pre-
vent SLE-associated ED. The present study was designed
to assess the effect of HCQ on endothelial function in a
murine model of SLE and its underlying mechanism.
Methods
Animal treatment
All experiments were carried out in accordance with
European Union Council Directive 2010/63/EU. Female
NZB/W F1 (NZ) mice and C57BL/6 J mice (controls; Ctrl)
were obtained from Harlan Laboratories (Correzzana,
Italy) and housed in a specific pathogen-free barrier
facility. Starting from 12 weeks of age, the animals were
randomly allocated to receive HCQ (3 mg/kg/day) or
vehicle (sham) in the drinking water. The animals were
divided into four groups: untreated control (Ctrl; n = 15),
NZB/W F1 mice with untreated SLE (NZ; n = 30), control
treated with HCQ (Ctrl-HCQ; n = 30), and NZB/W F1
mice with SLE treated with HCQ (NZ-HCQ, N = 30). The
mice were treated for three different periods (6, 12, or
18 weeks) (Table 1). At the end of treatment, they were
killed while under avertin-induced anesthesia. The proto-
col was approved by the local University of Pisa ethics
committee on use and care of animals.
Serum and urinary assays
At the time the mice were killed, blood samples were col-
lected and immediately placed in heparinized tubes. Serum
was separated by centrifugation and stored at −70 °C.
Serum titers of anti–double-stranded DNA (anti-
dsDNA) autoantibodies were analyzed with a commer-
cial enzyme-linked immunosorbent assay kit (Alpha
Diagnostic International, San Antonio, TX, USA), 24-h
urinary protein excretion was collected in metabolic cages
and measured by dipstick analysis (Bayer, Leverkusen,
Germany). For both serum and urine assays, the person
who performed the measurements was blinded to the age
and treatment allocation of the mice.
Histopathology
The kidneys were excised, fixed overnight in 4 % formalin,
and embedded in paraffin. Sections (1–2 μm) were cut,
dewaxed, and stained with hematoxylin and eosin (H&E)
and periodic acid–Schiff (PAS). H&E- and PAS-stained
sections were evaluated for nephritis according to a modi-
fied score described by Tao et al. as follows [19]:
 Glomerulonephritis: 1, focal and mild
hypercellularity; 2, multifocal and moderate
hypercellularity with capillary dilation and mild
Table 1 24-h proteinuria
Age, wk Group Mean SD Group Mean SD Group Mean SD
8–12 NZ 0.30 0.1 NZHCQ 0.22 0.02 Ctrl 1.35 1.23
18 NZ 0.56 0.44 NZHCQ 0.18 0.40 Ctrl 0.46 0.42
20 NZ 3.5a 2.7 NZHCQ 0.43 0.15 Ctrl 0.78 0.6
24 NZ 4.06 2.8 NZHCQ 0.23 0.10 Ctrl 0.34 0.40
30 NZ 4.9 2.2 NZHCQ 0.35 0.34 Ctrl 0.27 0.07
36 NZ 12.5 3.5 NZHCQ 12.18
b 6.3 Ctrl 1.083 0.50
Ctrl untreated control, NZ female NZB/W F1, NZHCQ NZB/W F1 mice with systemic
lupus erythematosus treated with hydroxychloroquine, SD standard deviation
Data are presented in milligrams per 24 h
aP < 0.05 at 20 weeks vs. 18 weeks
bP < 0.05 at 36 weeks vs. 30 weeks
Virdis et al. Arthritis Research & Therapy  (2015) 17:277 Page 2 of 9
hyalinosis; 3, diffuse hypercellularity (>50 % of the
tuft) and capillary aneurysm; 4, extensive sclerosis
and/or crescents (more than three cell layers), tuft
obliteration, collapse
 Interstitial nephritis: 1, small foci of leukocyte
infiltration; 2, mild inflammation of individual
tubules or isolated atrophied tubules; 3, extensive
(>50 %) inflammation with large foci of tubular
atrophy; 4, nearly all of the interstitium inflamed
plus extensive tubular atrophy or necrosis
 Vascular lesions: 1, mild thickening of vessel wall,
mild infiltration of leukocytes around vessels; 2,
moderate thickening of the vessel wall,
inflammation of main arteries, small foci of
inflammatory cells around interlobular arteries; 3,
severe thickening (onion skin pattern) of vessel
walls, moderate leukocyte infiltration of small
arterial branches; 4, vasculitis, fibrinoid necrosis
The nephritis score is the sum of the individual scores
ranging from 0 to 12. The images were acquired using
an Axio Imager Z1 microscope (Carl Zeiss MicroIma-
ging, Jena, Germany). All evaluations were performed in
a blinded manner.
Preparation of small mesenteric arteries and functional
experiments
A second-order branch of the mesenteric arterial tree
was dissected and mounted on two-glass microcannu-
lae in a pressurized myograph (model 110P; Danish
Myo Technology, Aarhus, Denmark) as previously de-
scribed [20]. Media and lumen dimensions were mea-
sured with the intraluminal pressure maintained at
45 mmHg.
Endothelium-dependent and -independent relaxations
were assessed by measuring the dilatory responses of
mesenteric arteries to cumulative concentrations of
acetylcholine (ACh, 0.001–100 μM; Sigma-Aldrich, St.
Louis, MO, USA) and sodium nitroprusside (SNP,
0.01–100 μΜ; Sigma-Aldrich). Vessels were precon-
tracted with norepinephrine (10 μM; Sigma-Aldrich).
This concentration was determined in dose titration
experiments to establish the threshold concentration
able to elicit similar contractions among the experi-
mental groups. To evaluate NO availability and ROS
production, ACh concentration–response curves were
constructed before and after 30-minute preincubation
with the NOS inhibitor Nω-nitro-L-arginine methyl ester
(L-NAME, 100 μM; Sigma-Aldrich) or the antioxidant
ascorbic acid (10 mM, 30-minute preincubation; Sigma-
Aldrich). To evaluate whether oxidative stress could
influence NO availability, an additional ACh curve was
constructed for simultaneous incubation with L-NAME
and ascorbic acid.
Involvement of NAD(P)H oxidase in endothelium-dependent
relaxation
To ascertain the contribution of NAD(P)H oxidase to ED
in additional experiments on NZ vessels (n = 6 each group),
an ACh curve was constructed after 30-minute incubation
with two different NAD(P)H oxidase inhibitors, apocynin
(Apo, 10 μM; Fluka-Sigma-Aldrich, St. Gallen, Switzerland)
and diphenyleneiodinium (DPI, 10 μM; Sigma-Aldrich)
[21]. To assess the possibility that NAD(P)H oxidase could
affect NO availability, Ach was infused under simultaneous
incubation with L-NAME and Apo or DPI.
Detection of vascular superoxide anion generation
The in situ production of superoxide anion was measured
by means of the fluorescent dye dihydroethidium (DHE;
Sigma-Aldrich) as previously described [22]. Each segment
was analyzed simultaneously after incubation with Apo
(100 μM) or Krebs solution. Additional incubations with
the superoxide scavenger polyethylene glycol superoxide
dismutase (PEG-SOD, 600 U ml−1; Sigma-Aldrich) were
performed as technical positive controls.
Data analysis
Maximal ACh- and SNP-induced responses (Emax) were
calculated as maximal percentage increments of lumen
diameter. The results are presented as mean ± SEM. The
statistical significance of relaxation responses was assessed,
taking into consideration the time course and treatment
by two-way analysis of variance (ANOVA). Other compar-
isons were made by repeated-measures ANOVA or by
one-way ANOVA followed by a Student-Newman-Keuls
test, where appropriate. A value of P < 0.05 was considered
statistically significant. The variable n indicates the num-
ber of experiments. All analyses were performed using





In the NZ group, the baseline (weeks 8–12) levels of 24-h
urinary protein excretion was 0.154 ± 0.53 mg. It started
to increase at 18 weeks (mean 3.5 ± 2.7 mg; P = 0.04), and
40 % of animals had proteinuria ≥100 mg/dl. Proteinuria
remained stable during the following weeks (4.06 ± 2.8 mg
at 24 weeks, 4.9 ± 2.2 mg at 30 weeks; P = ns) and in-
creased at 36 weeks (12.5 ± 3 mg; P > 0.001) (Table 1).
In the NZ-HCQ group, proteinuria was stable across 12–
30 weeks of age, with no significant differences between
baseline (0.22 ± 0.2 mg) and 30 weeks (0.35 ± 0.34 mg;
P = ns); however, significantly higher levels of pro-
teinuria were observed at 36 weeks (mean 12 ± 18 mg;
P < 0.001) (Table 1).
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In control mice, proteinuria was stable across 12–40
weeks of age (mean 1.44 ± 4.1 mg) (Table 1).
Anti-dsDNA autoantibody titers
Anti-dsDNA antibodies were detectable starting at
12 weeks of age in NZ mice (33 % positivity); however, a
significant increase in titers was observed thereafter,
with higher serological activity (87 % positivity) at
24 weeks of age (47 % positivity at 18 weeks, 67 % at
30 weeks). In the NZ-HCQ group, anti-dsDNA antibody
positivity at 24 weeks of age was 20 %, significantly
lower than that in the NZ mice (P = 0.002). At 30 weeks
of age, the anti-dsDNA positivity was 66 %, with no dif-
ferences from age-matched, untreated mice. Figure 1
shows the anti-dsDNA titers at different time points in
NZ, NZ-HCQ, and Ctrl mice.
Nephritis score
Initial histopathological lesions suggestive of nephritis
appeared on kidneys from NZ mice killed at 18 weeks of
age, then, the degree of nephritis increased progressively
until the last observation at age 36 weeks (mean score
2.75 ± 1.25). Similar nephritis scores were observed in
kidneys from NZ-HCQ mice at 24, 30, and 36 weeks of
age. These data are reported in Table 2.
No histopathological lesions suggestive of nephritis
were detected in control mice.
Endothelium-dependent relaxation in Ctrl and SLE mice:
role of NO availability and ROS production
In Ctrl animals, relaxation in response to ACh was pre-
served up to week 24 (Emax ACh, 12 weeks: 99.7 ± 0.6 %;
18 weeks: 99.8 ± 0.4 %; 24 weeks: 99.6 ± 0.7 %), but it was
attenuated at week 30 (90.0 ± 0.9 %) (Fig. 2a). L-NAME
significantly blunted the relaxation in response to ACh at
baseline and until 30 weeks, when a reduced inhibitory ef-
fect emerged (Fig. 3). Moreover, ascorbic acid was ineffect-
ive in changing the vascular response to ACh at baseline
(Emax ACh + ascorbic acid: 99.1 ± 0.4 %) and until 30 weeks
(Emax ACh + ascorbic acid, 12 weeks: 98.2 ± 0.7 %;
24 weeks: 98.4 ± 0.9 %; 30 weeks: 98.3 ± 0.6 %), when it
normalized the relaxation response to ACh (Emax ACh +
ascorbic acid: 96.9 ± 0.4 %) and restored the inhibitory
effect of L-NAME on ACh (54.8 ± 0.9 %).
In NZ mice, relaxation in response to ACh, though pre-
served at baseline (12 weeks: 99.8 ± 0.4 %), was signifi-
cantly reduced at week 18 (87.9 ± 1.1 %; P < 0.05 vs. Ctrl),
with further progressive decline by week 24 (72.3 ± 1.2 %;
P < 0.01 vs. Ctrl) and week 30 (62.0 ± 0.6 %; P < 0.01 vs.
Ctrl) (Fig. 2b). The inhibition of L-NAME on ACh was
preserved at baseline (Fig. 3) but started to decline at
18 weeks, with a progressive decrement at 24 and
30 weeks, at which point the response to ACh was
virtually resistant to L-NAME (Fig. 2). Ascorbic acid nor-
malized the relaxation in response to ACh in all groups
(Emax Ach + ascorbic acid, 18 weeks: 94.0 ± 1.2 %;
24 weeks: 93.5 ± 1.2 %; 30 weeks: 95.3 ± 0.6 %; P =N.S. vs.
baseline) and restored the inhibitory effect of L-NAME on
ACh (18 weeks: 52.7 ± 2.4 %; 24 weeks: 50.9 ± 2.1 %;
30 weeks: 53.6 ± 2.9 %). Relaxation in response to SNP
started to decline at week 30 among Ctrl mice (decrement
above baseline −10.3 ± 1.1 %; P < 0.05). A significant
decrement of vascular response to SNP at week 30
was also evident in the SLE group (decrement above
baseline −24.3 ± 1.4 %; P < 0.001), with a greater re-
duction (P < 0.05) compared with the age-matched
Ctrl group.
Effects of HCQ on vascular reactivity
Among NZ-HCQ mice, in the 18-week and 24-week sub-
groups, HCQ administration normalized the relaxation in
response to ACh (Fig. 2c) and restored the inhibition by
L-NAME on ACh (Fig. 3). In older NZ animals, HCQ po-
tentiated, without normalizing, the relaxation in response
to ACh and partly restored the L-NAME effect on
Fig. 1 Anti–double-stranded DNA (anti-dsDNA) levels at different
time points. The results are expressed as optical density (OD)
(mean of the OD readings of serum at 450 nm) as measured using
a microtiter plate reader (Ultrospec 2000; Amersham Pharmacia
Biotech, Little Chalfont, UK). *P = 0.02 in NZB/W F1 mice treated with
hydroxychloroquine (NZ-HCQ) vs. NZB/W F1 (NZ) mice at 24 weeks
Table 2 Histopathology
Age, wk Nephritis score (mean ± SD) P value
NZ NZ-HCQ
12 0 ± 0 – n.s.
18 0.4 ± 0.5 – n.s.
24 0.75 ± 0.5 2 ± 0.5 n.s.
30 1 ± 0.9 2 ± 0.5 n.s.
36 2.8 ± 1.2 3 ± 4.6 n.s.
n.s. not significant, NZ NZB/W F1 mice, NZ-HCQ NZB/W F1 mice treated with
hydroxychloroquine, SD standard deviation
Virdis et al. Arthritis Research & Therapy  (2015) 17:277 Page 4 of 9
Fig. 2 Relaxations in response to acetylcholine in mesenteric arteries at baseline and different time points in control mice (a), NZB/W F1 mice
(NZ) (b) or NZB/W F1 mice treated with hydroxychloroquine (NZ-HCQ) (c). Each point represents the mean ± SEM of eight experiments.
*P < 0.05; †P < 0.01
Fig. 3 Inhibitory effects of Nω-nitro-L-arginine methyl ester (L-NAME) on acetylcholine-induced maximal relaxation at baseline and different time points
in control C57BL/6 J mice (Ctrl), NZB/W F1 mice (NZ), and NZB/W F1 mice treated with hydroxychloroquine (NZ-HCQ). Each column represents the
mean ± SEM of eight experiments. *P < 0.001; **P < 0.05 vs. other Ctrl groups; ***P < 0.01; †P < 0.01 vs. NZ baseline; ‡P < 0.01 vs. 18-week-old NZ;
¶P < 0.01 vs. 24-week-old NZ. Apo apocynin
Virdis et al. Arthritis Research & Therapy  (2015) 17:277 Page 5 of 9
endothelium-dependent dilation (Figs. 2c and 3). HCQ
was totally ineffective in modulating endothelial function
in Ctrl animals (Additional file 1).
Involvement of NAD(P)H oxidase in endothelium-dependent
relaxation
In the Ctrl group, the relaxation in response to ACh was
not modified by Apo at any time point (Additional file 1).
In contrast, in the NZ group, Apo, while ineffective at
baseline, normalized the response to ACh at 18 and
24 weeks (Additional file 2) and restored the inhibitory
effect of L-NAME on ACh (Fig. 3). Of note, at 30 weeks,
Apo improved the relaxation in response to ACh
(Additional file 2), although it did not normalize it, and
partly ameliorated the inhibitory effect of L-NAME on the
endothelial agonist (Fig. 3). Similar results were obtained
with DPI, which normalized the vascular response to ACh
in NZ mice at 18 and 24 weeks and restored the inhibitory
effect of L-NAME on ACh (Additional file 3). At 30 weeks,
DPI only in part potentiated the response to ACh and the
inhibition by L-NAME (Additional file 3).
In the NZ-HCQ groups, Apo incubation was devoid of
any effect, at any time, either on the response to ACh or
on the inhibition by L-NAME (Fig. 3).
DHE analysis of vascular superoxide anion generation
At baseline, DHE red fluorescence revealed a weak and
similar mesenteric superoxide anion production among
the Ctrl and NZ groups (Fig. 4). In the Ctrl group,
advancing age failed to elicit any significant increment of
superoxide generation. In contrast, in NZ mice, a dra-
matic increment of superoxide anion production was
already present in the 18-week group, with a progressive
production at week 24 and a further generation at
30 weeks (Fig. 4). Incubation with Apo prevented the
superoxide production at any time point (Fig. 4). Like-
wise, in the NZ-HCQ group, superoxide production was
completely abrogated (Fig. 4). As technical positive con-
trols, in vessels from NZ mice incubated with PEG-SOD,
the superoxide generation was completely abolished
(Fig. 4).
Discussion
In the present study, we have shown that the early ad-
ministration of HCQ is able to prevent the development
of ED in a murine model of SLE.
Endothelial function impairment has been described
previously in mice as well as in human SLE [23–30]. In
our mouse model, ED occurred at a very early stage of
the disease in the absence of overt disease activity. As
early as 18 weeks of age, mesenteric small arteries from
the NZ group already showed a blunted endothelium-
dependent relaxation, together with a reduced inhibitory
effect of L-NAME on ACh, and at this stage anti-
dsDNA antibodies were positive, and only initial urinary
abnormalities were detectable in some mice. DHE ana-
lysis revealed a dramatic increment of vascular super-
oxide anion generation.
To exclude that these effects might be caused by age-
ing per se, a well-recognized major contributor to vas-
cular functional changes [31], the results from each time
of exposure to the disease were compared with data ob-
tained in age-related control groups. Indeed, vessels
from control mice showed a preserved inhibitory effect
of L-NAME on endothelium-dependent relaxation and
no evidence of ROS generation up to 30 weeks. At this
age, the control group displayed a reduced NO availa-
bility, but this reduction was less pronounced than in
the NZ group, without any increased ROS production.
Therefore, these data indicate that SLE-associated ED is
a functional vascular alteration occurring early in the
disease course, regardless of disease activity and aging.
These observations fully support the observation made
in patients with SLE who might experience premature
atherosclerosis independently of traditional risk factors
for CV disease [3, 32].
In our model, early and long-term HCQ administration,
though ineffective in modulating endothelial function in
control mice, normalized the endothelium-dependent re-
laxation and the inhibitory effect of L-NAME on ACh as
well, in both 8-week-old and 24-week-old NZ mice. This
protective effect, although still evident, was only partially
effective in NZ at 30 weeks of age.
It is well known that renal involvement itself can cause
ED. Thus, the observed beneficial effect of HCQ on endo-
thelial function might be consequent to an improvement
of kidney disease [33]. However, in our experimental
model, this is an unlikely hypothesis, considering that the
reversal of ED induced by HCQ occurred before the
occurrence of overt kidney disease. In addition, even if
chronic administration of HCQ has a positive effect on
proteinuria and anti-dsDNA autoantibodies, histological
analysis revealed a comparable activity and damage scores
in the kidneys from HCQ-treated and untreated mice. In
conjunction, these findings indicate that the protective
vascular effects by HCQ were not exclusively related to
kidney disease and suggest the ability of the drug to inter-
fere with the vascular inflammatory process and the im-
munological mechanisms accounting for ED, as previously
demonstrated [34–37].
Apo, an NAD(P)H oxidase inhibitor, normalized the
inhibitory effect of L-NAME on ACh-induced relaxation
up to 30 weeks of age. Moreover, DHE staining showed
that Apo prevented the SLE-induced vascular ROS at
any time point of the disease.
On the basis of these findings, it is conceivable that
NAD(P)H oxidase is a major enzymatic pathway that
mediates vascular ROS production in this model of
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SLE, a process that likely initiates at a very early stage
of the disease.
Indeed, the present data extend the previous demon-
stration of the beneficial effect of HCQ on large arteries
[17] to the peripheral microcirculation and demonstrate
a property of this compound of delaying the onset of
vascular functional alterations for a long period.
The main novelty of the data relies on the fact that
our work offers a different perspective, given that early
disease is the main focus of the study.
Fig. 4 Dihydroethidium (DHE) staining for detection of superoxide production. Representative DHE staining (upper panels) and quantitative analysis of
the red signal (lower panels; original magnification, ×40) in mesenteric arteries from C57BL/6 J mice control mice (Ctrl) and NZB/W F1 mice (NZ) at
baseline, from NZ groups without or with apocynin (Apo) or polyethylene glycol superoxide dismutase (PEG-SOD), and from NZB/W F1 mice treated
with hydroxychloroquine (NZ-HCQ) at different time points. Each column represents the mean ± SEM of six experiments. *P < 0.001; †P < 0.05
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Indeed, in 2010, Thacker et al. [23] described an im-
paired endothelial-dependent vasorelaxation at the aortic
level at 36 weeks of age in the same model, in concomi-
tance with an overt disease expression. However, in line
with our observations, they also showed an earlier im-
pairment in phenotype and function of endothelial pro-
genitor cells, before full disease expression [23].
More recently, Gómez-Guzmán et al. [17], in the same
SLE model, described the protective effect of a short course
of HCQ on vascular parameters (hypertension, heart rate,
cardiac hypertrophy) as well as on disease-related variables.
Similar to us, they found, even if in a large vessel bed such
as the aorta, a beneficial effect of HCQ on endothelium-
dependent vasodilation on vascular ROS levels and
NADPH oxidase activity. However, with respect to our
study, the authors started the treatment in an advanced dis-
ease stage, after a long-standing autoimmune-mediated in-
flammatory process. Thus, we can postulate that what we
observed is not only the result of an immunological process
but also a mixture of metabolism, purely CV detriment,
and aging. This is supported by the fact that the administra-
tion of a mixture of antioxidants yielded similar results [17].
Some limitations of this study have to be acknowledged.
First, we have histological data of the kidney from ad-
vanced disease, but no earlier evaluations (18–20 weeks of
age) were available. This aspect can account for some
discrepancy observed between the proteinuria trend and
the kidney histology between treated and untreated mice.
Indeed, whereas a delay in proteinuria occurrence has
been observed in mice during HCQ treatment, this effect
was not reflected by the later histology scores. Second, no
serial data on anti-dsDNA antibody activity were available
from each mouse, because blood samples were taken only
at the time they were killed. This could reduce the accur-
acy in defining disease progression. Moreover, the mice
were given the HCQ in their drinking water; although this
is a common practice, variations in individual mice as to
intake cannot be excluded.
Conclusions
This study shows that early treatment with HCQ is able to
reduce early ED related to the inflammatory process in a
mouse model of SLE. These data may support the clinical
observations of the potential beneficial effect of HCQ in
preventing vascular damage in human SLE and may sup-
port the early introduction of HCQ in patients with recent
disease onset.
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